MaxCyte, Inc.
MXCT
Rank in Stocks
#18406
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes... MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Share Price
$1.30
Last synced: 2026-11-09
Market Cap
$134.17M
Change (1 day)
3.17%
Change (1 year)
-17.72%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade MaxCyte, Inc. (MXCT)
Category
Healthcare
P/B ratio for MaxCyte, Inc. (MXCT)
P/B ratio as of November 2026 TTM: 1.07
According to MaxCyte, Inc.'s latest financial reports and stock price, its current price-to-book ratio (TTM) is 1.07. At the end of 2025 the company had a P/B ratio of 0.96.
P/B ratio history for MaxCyte, Inc. from 2012 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 1.07 | 11.45% |
| 2025 | 0.96 | -54.52% |
| 2024 | 2.11 | 1.16% |
| 2023 | 2.09 | -4.39% |
| 2022 | 2.19 | -37.75% |
| 2021 | 3.51 | -90.12% |
| 2020 | 35.54 | -49.58% |
| 2019 | 70.49 | -0.50% |
| 2018 | 70.85 | 67.89% |
| 2017 | 42.20 | -62.35% |
| 2016 | 112.08 | -146.75% |
| 2015 | -239.74 | 1,914.55% |
| 2014 | -11.90 | -97.51% |
| 2013 | -478.87 | -61.72% |
| 2012 | -1.25K | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 7.0081 | 555.02% |
US
|
|
| 12.9864 | 1,113.80% |
US
|
|
| 4.5726 | 327.39% |
AU
|
|
| 4.5877 | 328.80% |
BE
|
|
| 6.7286 | 528.90% |
NL
|
Questions about MaxCyte, Inc.'s P/B ratio
What is MaxCyte, Inc.'s P/B ratio?
MaxCyte, Inc.'s P/B ratio is 1.07, as of Nov 2026.
What was MaxCyte, Inc.'s P/B ratio in 2025?
In 2025, MaxCyte, Inc.'s P/B ratio was 0.96, compared with 2.11 in 2024.
How has MaxCyte, Inc.'s P/B ratio changed since 2020?
From 2020 to 2025, MaxCyte, Inc.'s P/B ratio was highest in 2020 (35.54) and lowest in 2025 (0.96).
How does MaxCyte, Inc.'s P/B ratio compare with similar companies?
MaxCyte, Inc.'s P/B ratio (1.07) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 12.99.